Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Zai Lab (NASDAQ: ZLAB).The analyst commented, “Bemarituzumab (anti-FGFR2b mAb, bema) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE